Related Experiment Video
Updated: Mar 9, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer
Yujiang Fang1,2, Lei Zhao3, Huaping Xiao4,5
1Department of Microbiology, Immunology and Pathology, College of Osteopathic Medicine, Des Moines University, Des Moines, IA, 50312, USA. yujiang.fang@dmu.edu.
Abstract:
IL-33 is a member of the IL-1 family of cytokines, and no study has been performed to address its direct anti-tumor effect. This study is designed to investigate whether IL-33 has any direct effect on pancreatic cancer. Clonogenic survival assay, immunohistochemistry, TUNEL staining, proliferation, caspase-3 activity kits and RT-PCR were used to evaluate the effects of IL-33 on cell survival, proliferation and apoptosis of a pancreatic cancer cell line, MIA PaCa-2. We found that the percentage of colonies of MIA PaCa-2 cells, PCNA+ cells and the OD value of cancer cells were all decreased in the presence of IL-33. TUNEL+ cells and the relative caspase-3 activity in cancer cells were increased in the presence of IL-33. We further found that its anti-proliferative effect on cancer cells correlated with downregulation of pro-proliferative molecules cdk2 and cdk4 and upregulation of anti-proliferative molecules p15, p21 and p53. Its pro-apoptotic effect correlated with downregulation of anti-apoptotic molecule FLIP and upregulation of pro-apoptotic molecule TRAIL. These results suggest that IL-33 presents significant anti-tumor effects by inhibition of proliferation and induction of apoptosis of MIA PaCa-2 pancreatic cancer cells. Thus, strength of IL-33/ST2 signal pathway might be a promising way to treat pancreatic cancer.
Insights
Interleukin-33 (IL-33) demonstrates direct anti-tumor effects against pancreatic cancer by inhibiting cell proliferation and inducing apoptosis. This suggests the IL-33/ST2 pathway could be a novel therapeutic target for pancreatic cancer treatment.
Area of Science:
- Immunology
- Oncology
Background:
- Interleukin-33 (IL-33) is part of the IL-1 cytokine family.
- No prior studies have investigated the direct anti-tumor effects of IL-33.
Purpose of the Study:
- To determine if IL-33 has a direct anti-cancer effect on pancreatic cancer cells.
- To explore the mechanisms underlying IL-33's potential anti-tumor activity.
Main Methods:
- Utilized MIA PaCa-2 pancreatic cancer cell line.
- Assessed cell survival, proliferation, and apoptosis using clonogenic assays, immunohistochemistry, TUNEL staining, caspase-3 activity kits, and RT-PCR.
Main Results:
- IL-33 significantly reduced MIA PaCa-2 cell colony formation, proliferation (PCNA+ cells), and OD values.
- IL-33 increased apoptosis (TUNEL+ cells) and caspase-3 activity.
- IL-33 modulated key cell cycle regulators (downregulating CDK2/4, upregulating p15/p21/p53) and apoptosis-related molecules (downregulating FLIP, upregulating TRAIL).
Conclusions:
- IL-33 exhibits direct anti-tumor properties against pancreatic cancer cells by suppressing proliferation and promoting apoptosis.
- The IL-33/ST2 signaling pathway represents a potential therapeutic strategy for pancreatic cancer.
